The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Focal Segmental Glomerulosclerosis Market In 2026 And What Value Is Projected For 2030?
The focal segmental glomerulosclerosis market has experienced substantial growth in recent years. It is projected to expand from $1.57 billion in 2025 to $1.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. Historically, this market’s development has been driven by factors such as the prevalence of proteinuria, the increasing burden of chronic kidney disease, the application of corticosteroids, the expansion of nephrology clinics, and the growth of dialysis infrastructure.
The market for focal segmental glomerulosclerosis is projected to experience robust expansion over the coming years, anticipated to reach a valuation of $2.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. Key drivers for this growth during the forecast period include advancements in precision nephrology, the emergence of early disease biomarkers, ongoing biologic drug development, the broadening of transplant programs, and increased funding for rare kidney diseases. Significant trends identified for the forecast period encompass an enhanced focus on targeted immunosuppressive therapies, the increasing embrace of combination drug regimens, wider availability of early diagnostic screening, a surge in the application of renin-angiotensin system inhibitors, and improved readiness for kidney transplants.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24541&type=smp
What Drivers Are Influencing The Focal Segmental Glomerulosclerosis Market?
The increasing occurrence of kidney ailments is projected to boost the expansion of the focal segmental glomerulosclerosis market in the foreseeable future. Kidney diseases encompass conditions that compromise the kidneys’ structure and function, thereby impacting their capacity to filter waste, maintain fluid balance, and govern vital bodily processes. This surge in kidney disease cases is largely attributable to diabetes, where prolonged elevated blood sugar levels cause harm to the kidney’s filtering units, resulting in diabetic nephropathy. Focal segmental glomerulosclerosis specifically denotes the gradual scarring of kidney filters, acting as a crucial marker and focus point for the comprehension, diagnosis, and management of chronic kidney conditions. For example, data from August 2025, provided by the American Kidney Fund, a U.S. nonprofit, indicates that 35.5 million Americans currently have chronic kidney disease (CKD), approximately 815,000 Americans are experiencing kidney failure, and close to 555,000 Americans are undergoing dialysis. Consequently, the growing incidence of kidney diseases is fueling the focal segmental glomerulosclerosis market.
What Are The Key Segments Of The Focal Segmental Glomerulosclerosis Market?
The focal segmental glomerulosclerosis market covered in this report is segmented –
1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes
What Key Trends Are Influencing The Development Of The Focal Segmental Glomerulosclerosis Market?
Leading companies in the focal segmental glomerulosclerosis market are concentrating on developing innovative treatments, such as non-immunosuppressive oral medication, to enhance patient outcomes and mitigate treatment side effects. This type of oral medication is ingested and addresses the condition without weakening the immune system, effectively managing focal segmental glomerulosclerosis by directly targeting kidney damage and avoiding immune-related complications. For example, in May 2025, Travere Therapeutics Inc., a US-based biopharmaceutical company, received traditional approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), indicated for the treatment of focal segmental glomerulosclerosis (FSGS). FILSPARI is a first-in-class therapy that operates by simultaneously blocking both the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual mechanism substantially reduces proteinuria in conditions such as FSGS and IgA nephropathy. When compared to current treatments, FILSPARI offers enhanced kidney protection while maintaining a strong safety profile.
Who Are The Leading Companies Operating In The Focal Segmental Glomerulosclerosis Market?
Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.
Read the full focal segmental glomerulosclerosis market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Focal Segmental Glomerulosclerosis Market?
North America was the largest region in the focal segmental glomerulosclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Focal Segmental Glomerulosclerosis Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24541&type=smp
Browse Through More Reports Similar to the Global Focal Segmental Glomerulosclerosis Market 2026, By The Business Research Company
Focal Segmental Glomerulosclerosis Drugs Market Report 2026
Kidney Disease Market Report 2026
https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report
Rare Kidney Diseases Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model